Granted Patent
B2
US 12,653,874 · App. 17/880,558 · Granted Jun 16, 2026
Nant cancer vaccine
Inventors:
Patrick Soon-Shiong (Culver City, CA); Kayvan Niazi (Culver City, CA); Shahrooz Rabizadeh (Agoura Hills, CA); Hans G. Klingemann (Culver City, CA); Laurent H. Boissel (Culver City, CA); Barry J. Simon (Culver City, CA)
A61K39/001152A61K38/2013A61K38/2046A61K38/2086A61K39/0011A61K39/001106A61K39/001164A61K39/00117A61K39/001182A61K40/15A61K40/31A61K40/4205A61K40/4242A61K40/4253A61K40/4257A61K40/4266C07K16/2827A61K2039/507A61K2039/523A61K2239/31A61K2239/38A61K2239/48A61K2239/57C07K2317/76
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Cancer is treated using coordinated treatment regimens that uses various compounds and compositions that drive a tumor from the escape phase of cancer immunoediting to the elimination and equilibrium phase of cancer immunoediting.
Claims (19)
1 . A method of treating cancer in a patient in need thereof, the method comprising:
administering to the patient a sequence of therapeutics,
wherein the sequence comprises Nab-paclitaxel, target activated natural killer (taNK) cells, wherein the taNK cells comprise a chimeric antigen receptor (CAR) comprising an extracellular domain having binding affinity for a tumor-specific antigen, and IL-15 or IL-15N72D;
wherein the therapeutics are administered in cycles; and
wherein within the cycle the Nab-paclitaxel and taNK cells are administered before the IL-15 or IL-15N72D.
2 . The method of claim 1 , wherein the tumor specific antigen is PD-L1.
3 . The method of claim 1 , wherein the IL-15N72D is ALT-803.
4 . The method of claim 1 , wherein the Nab-paclitaxel is administered on days 1 and 8 of the cycle.
5 . The method of claim 1 , wherein the taNK cells are administered on days 1 and 8 of the cycle.
6 . The method of claim 3 , wherein the taNK cells and the Nab-paclitaxel are administered intravenously (IV), and wherein the ALT-803 is administered subcutaneously.
7 . The method of claim 2 , wherein the PD-L1 taNK dose comprises 4×10 9 cells.
8 . The method of claim 3 , wherein the ALT-803 dose comprises 15 μg/kg.
9 . The method of claim 1 , wherein the sequence further comprises cyclophosphamide.
10 . The method of claim 9 , wherein the cyclophosphamide dose comprises 50 mg, administered orally and twice daily.
11 . The method of claim 1 , wherein the sequence further comprises albumin-bound doxorubicin.
12 . The method of claim 11 , wherein the albumin-bound doxorubicin dose comprises 150 mg/m 2 .
13 . The method of claim 11 , wherein the albumin-bound doxorubicin is administered IV.
14 . The method of claim 1 , wherein the sequence further comprises low dose radiation.
15 . The method of claim 1 , wherein the cycles are weekly, every two weeks, or every three weeks.
Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jan 30, 2025
From: NANT HOLDINGS IP, LLC
To: IMMUNITYBIO, INC.
Reel/Frame 070063/0186 →
SECURITY INTEREST
Recorded Jan 2, 2024
From: IMMUNITYBIO, INC.; NANTCELL, INC.; RECEPTOME, INC.; VBC HOLDINGS LLC; ALTOR BIOSCIENCE, LLC; ETUBICS CORPORATION; IGDRASOL, INC.
To: INFINITY SA LLC, AS PURCHASER AGENT
Reel/Frame 066179/0074 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Sep 12, 2022
From: SIMON, BARRY J.
To: IMMUNITYBIO, INC.
Reel/Frame 061065/0909 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Sep 12, 2022
From: NIAZI, KAYVAN; RABIZADEH, SHAHROOZ; KLINGEMANN, HANS G.; BOISSEL, LAURENT H.
To: NANTCELL, INC.
Reel/Frame 061065/0935 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Sep 12, 2022
From: SOON-SHIONG, PATRICK
To: NANT HOLDINGS IP, LLC
Reel/Frame 061065/0987 →
Continuity (12)
Continuation
16312246
Continuation
16312246
Provisional Application
62474034
· Mar 20, 2017
Provisional Application
62473207
· Mar 17, 2017
Provisional Application
62463037
· Feb 24, 2017
Provisional Application
62404753
· Oct 5, 2016
Provisional Application
62393528
· Sep 12, 2016
Provisional Application
62371665
· Aug 5, 2016
Provisional Application
62357324
· Jun 30, 2016
References Cited (153)
US 7758891B2
· Desai et al.
· 2010
[cited by applicant]
US 7771751B2
· Desai et al.
· 2010
[cited by applicant]
US 7780984B2
· Desai et al.
· 2010
[cited by applicant]
US 7981445B2
· De et al.
· 2011
[cited by applicant]
US 8034375B2
· Desai et al.
· 2011
[cited by applicant]
US 9492499B2
· Jaynes et al.
· 2016
[cited by applicant]
US 9683048B2
· Freeman et al.
· 2017
[cited by applicant]
US 20120059670A1
· Sanborn et al.
· 2012
[cited by applicant]
US 20120066001A1
· Sanborn et al.
· 2012
[cited by applicant]
US 20140012843A1
· Soon-Shiong
· 2014
[cited by applicant]
US 20140114675A1
· Soon-Shiong
· 2014
[cited by applicant]
US 20150032468A1
· Soon-Shiong
· 2015
[cited by applicant]
US 20150125463A1
· Cogswell et al.
· 2015
[cited by applicant]
US 20150231241A1
· Chang et al.
· 2015
[cited by applicant]
US 20160095942A1
· Markovic et al.
· 2016
[cited by applicant]
US 20180222982A1
· Dranoff et al.
· 2018
[cited by applicant]
US 20190134174A1
· Jones et al.
· 2019
[cited by applicant]
US 20200171137A1
· Soon-Shiong et al.
· 2020
[cited by applicant]
CA 3027911A1
· 2018
[cited by applicant]
CN 104861067A
· 2015
[cited by applicant]
CN 109789190A
· 2019
[cited by applicant]
JP 2011225538A
· 2011
[cited by applicant]
JP 2019524692A
· 2019
[cited by applicant]
KR 1020190031492A
· 2019
[cited by applicant]
MX 2018015796A
· 2019
[cited by applicant]
TW 201803598A
· 2018
[cited by applicant]
WO 2011139345A2
· 2011
[cited by applicant]
WO 2013062505A1
· 2013
[cited by applicant]
WO 2013192339A1
· 2013
[cited by applicant]
WO 2014059036A1
· 2014
[cited by applicant]
WO 2014163684A1
· 2014
[cited by applicant]
WO 2014193982A1
· 2014
[cited by applicant]
WO 2014210611A1
· 2014
[cited by applicant]
WO 2015069770A1
· 2015
[cited by applicant]
WO 2015095811A2
· 2015
[cited by applicant]
WO 2015097536A2
· 2015
[cited by applicant]
WO 2015184439A1
· 2015
[cited by applicant]
WO 2016004060A2
· 2016
[cited by applicant]
WO 2016004876A1
· 2016
[cited by applicant]
WO 2016057554A1
· 2016
[cited by applicant]
WO 2016061142A1
· 2016
[cited by applicant]
WO 2016118527A1
· 2016
[cited by applicant]
WO 2016164833A1
· 2016
[cited by applicant]
WO 2016172722A1
· 2016
[cited by applicant]
WO 2017035392A1
· 2017
[cited by applicant]
WO 2017066256A2
· 2017
[cited by applicant]
WO 2017100338A1
· 2017
[cited by applicant]
WO 2017139725A1
· 2017
[cited by applicant]
WO 2017161360A2
· 2017
[cited by applicant]
WO 2017205810A1
· 2017
[cited by applicant]
WO 2017210579A1
· 2017
[cited by applicant]
WO 2018005973A1
· 2018
[cited by applicant]
WO WO2021108641A1
· 2021
[cited by examiner]
Sow et al., “Combining low-dose or metronomic chemotherapy with anticancer vaccines—A therapeutic opportunity for lymphomas”, Oncolmmunology 2:12, Dec. 2013.
[cited by applicant]
Mittal et al., “New insights into cancer immunoediting and its three component phases—elimination, equilibrium and escape”, Current Opinion in Immunology, vol. 27: pp. 16-25, 2014.
[cited by applicant]
1st Examination Report issued Oct. 2, 2019 in Australian Patent Application No. 2017290803, 8 pages.
[cited by applicant]
Schreiber et al., “Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion”, Science, Mar. 25, 2011, vol. 331, pp. 1565-1570 (Cited from Specification).
[cited by applicant]
Muenst et al., “The immune system and cancer evasion strategies: therapeutic concepts”, Journal of Internal Medicine, 2016, vol. 279, pp. 541-562 (Cited from Specification).
[cited by applicant]
Zhu et al., “Novel Human Interleukin-15 Agonists”, J Immunol, 2009, vol. 183, pp. 3598-3607 (Cited from Specification).
[cited by applicant]
Kaufman et al., “Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial”, Lancet Oncol., Oct. 2016, vol. 17, No. 10, pp. 1-28 (Cited fr…
[cited by applicant]
Balint et al., “Extended evaluation of a Phase 1/2 trial on dosing, safety, immunogenicity, and overall survival after mmunizations with an advanced generation Ad5 [E1-, E2b-]-CEA{6D) vaccine in late stage colorectal ca…
[cited by applicant]
Morse et al., “Novel Adenoviral Vector Induces T Cell Responses Despite AntiAdenoviral Neutralizing Antibodies in Colorectal Cancer Patients”, Cancer Immunol Immunother., Aug. 2013, vol. 62, No. 8, p. 1-16 (Cited from S…
[cited by applicant]
Gabitzsch et al., “An Ad5[E1-, E2b-]-HER2/neu vector induces immune responses and inhibits HER2/neu expressing tumor progression in Ad5 immune mice”, Cancer gene therapy, 2011, vol. 18, pp. 326-335 (Cited from Specifica…
[cited by applicant]
Gabitzsch et al., “The generation and analyses of a novel combination of recombinant adenovirus vaccines targeting three tumor antigens as an immunotherapeutic”, Oncotarget, Sep. 2015, vol. 6, No. 31, pp. 31344-31359.
[cited by applicant]
Heery et al., “Phase I trial of a yeast-based therapeutic cancer vaccine (GI-6301) targeting the transcription factor brachyury”, Cancer Immunol Res., Nov. 2015, vol. 3, No. 11, pp. 1248-1256 {Cited from Specification).
[cited by applicant]
The Partial Supplementary European Search Report received for European Patent Application Serial No. 17821361.7 dated Jan. 31, 2020, 24 pages.
[cited by applicant]
Hodson J., “NantBioScience and NantKwest Partner with the National Cancer Institute to Further Develop Recombinant NK Cells and Monoclonal Antibodies as Monotherapies and Combination Cancer Immunotherapies”, NantKwest, …
[cited by applicant]
Rhode et al., “Comparison of the super agonist complex, ALT-803, to IL-15 as cancer immunotherapeutics in animal models”, Cancer Immunol Res., Jan. 2016, vol. 4, No. 1, pp. 1-25.
[cited by applicant]
Hartley et al., “Pancreatic cancer, treatment options, and GI-4000”, Human Vaccines & Immunotherapeutics, vol. 10, No. 11, pp. 3347-3353.
[cited by applicant]
Epstein et al., “Identification of a Protein Fragment of Interleukin 2 Responsible for Vasopermeability”, Journal of the National Cancer Institute, May 21, 2003, vol. 95, No. 10, pp. 741-749.
[cited by applicant]
Atzpodien et al., “IL-2 in combination with IFN-a and 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trial”, British Journal of Cancer, 2001, vol. 85, No.…
[cited by applicant]
First Office Action received for Taiwan Patent Application Serial No. 106122120 dated Feb. 7, 2020, 12 pages (Including English Translation).
[cited by applicant]
International Preliminary Report on Patentability received for PCT Application Serial No. PCT/US2017/040297 dated Oct. 10, 2018, 07 pages.
[cited by applicant]
International Search Report and Written Opinion received for PCT Application Serial No. PCT/US2017/040297 dated Oct. 18, 2017, 15 pages.
[cited by applicant]
Communication pursuant to Rules 161 (2) and 162 EPC received for EP Patent Application Serial No. 17821361.7 dated Feb. 6, 2019, 03 page.
[cited by applicant]
Office Action Received in Canadian Patent Application Serial No. 3027911 dated Sep. 27, 2019, 6 pages.
[cited by applicant]
Stubbs et al., “Whole recombinant yeast vaccine activates dendritic cells and elicits protective cell-mediated Immunity”, Nat Med, 2001, vol. 7, 5 pages.
[cited by applicant]
Zhang et al., “Machine learning competition in immunology- Prediction of HLA class I binding peptides”, J Immunol Methods, Nov. 30, 2011, vol. 374, No. 1-2, p. 1-4 (Cited from Specification).
[cited by applicant]
Gong et al., “Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells”, Leukemia, Apr. 1, 1994, vol. 8, No. 4, pp. 652-658 (Cited from Specificati…
[cited by applicant]
Maki et al., “Factors regulating the cytotoxic activity of the human natural killer cell line, NK-92”, J Hematother Stem Cell Res, Jun. 2001, vol. 10, No. 3, pp. 369-383 (Cited from Specification).
[cited by applicant]
Klingemann et al., “A cytotoxic NK-cell line (NK-92) for ex vivo purging of leukemia from blood”, Biol Blood Marrow Transplant, May 1996, vol. 2, No. 2, pp. 68-75 (Cited from Specification).
[cited by applicant]
Examination report No. 2 received for Australian Patent Application Serial No. 2017290803 dated May 1, 2020, 4 pages.
[cited by applicant]
Floros et al., “Anticancer Cytokines: Biology and Clinical Effects of IFN-a2, IL-2, IL-15, IL-21, and IL-12”, Semin Oncol, 2015, vol. 42, No. 4, pp. 539-548.
[cited by applicant]
International Search Report and Written Opinion received for Singaporean Patent Application Serial No. 11201811074R dated Mar. 6, 2020, 10 pages.
[cited by applicant]
Non Final Office Action reveived for U.S. Appl. No. 16/783,734, dated Jul. 17, 2020, 133 pages.
[cited by applicant]
“MUSC launches first clinical trial involving twopowerful drugs for lung cancer”“, Eureka Alert! Public Release, URL: https://www.eurekalert.org/pub_releases/2016-01/muos-mlf011416.php, Jan. 14, 2016, 2 pages.”
[cited by applicant]
“Bristol-Myers Squibb and Celgene Enter Clinical Collaboration Agreement to Evaluate Immunotherapy and Chemotherapy Combination Regimen”, Bristol Myers Squibb Press Release, URL: https://news.bms.com/press-release/rd-ne…
[cited by applicant]
Klingemann et al, “Natural Killer Cells for Immunotherapy—Advantages of the NK-92 Cell Line over Blood NK Cells”, Frontiers in Immunology, Mar. 14, 2016, vol. 7, pp. 1-7.
[cited by applicant]
“Altor Bioscience Corporation Partners with the National Cancer Institute to Further Develop Altar's ALT-803 and ALT-801 CancerImmunothera peutics”“, Rx Times, URL: http://rxtimes.com/altor-bioscience-corporation-partne…
[cited by applicant]
Extended European search report received for EP Patent Application Serial No. 17821361.7 dated Jun. 26, 2020, 24 pages.
[cited by applicant]
Notice of Reasons for Refusal received for Japanese Patent Application Serial No. 2018-569023, dated Jun. 9, 2020, 8 pages. (Including English Translation).
[cited by applicant]
Office Action received for Korean Patent Application Serial No. 10-2019-7003046, dated Jun. 26, 2020, 11 pages. (Including English Translation).
[cited by applicant]
Requirement for Restriction/Election received for U.S. Appl. No. 16/312,246 dated Aug. 25, 2020, 11 pages.
[cited by applicant]
Mkrtichyan et al., “Anti-PD-1 synergizes with cyclophosphamide to induce potent anti-tumor vaccine effects through novel mechanisms”, Eur. J. Immunol., 2011, vol. 41, pp. 2977-2986.
[cited by applicant]
Examination report No. 3 received for Australian Patent Application Serial No. 2017290803 Aug. 14, 2020, 5 pages.
[cited by applicant]
Examination report No. 4 received for Australian Patent Application Serial No. 2017290803 Sep. 24, 2020, 3 pages.
[cited by applicant]
Examination report No. 5 received for Australian Patent Application Serial No. 2017290803 Sep. 28, 2020, 4 pages.
[cited by applicant]
Office Action received for Canadian Patent Application Serial No. 3027911 dated Sep. 24, 2020, 4 pages.
[cited by applicant]
Office Action received in Taiwanese Patent Application Serial No. 106122120 dated Sep. 16, 2020, 16 pages (Including English Translation).
[cited by applicant]
Non Final Office Action reveived for U.S. Appl. No. 16/312,246 dated Nov. 10, 2020, 158 pages.
[cited by applicant]
Daly et al., “Clinical Trials Integrating Immunotherapy and Radiation for Non-Small-Cell Lung Cancer”, Journal of Thoracic Oncology, 2015, vol. 10, No. 12, pp. 1685-1693.
[cited by applicant]
Alvarez et al., “Advances in immunotherapy for treatment of lung cancer”, Cancer Biology and Medicine, 2015, vol. 12, pp. 209-222.
[cited by applicant]
Final Office Action reveived for U.S. Appl. No. 16/783,734 dated Oct. 8, 2020, 30 pages.
[cited by applicant]
Mkrtichyan et al., “Anti-PD-1 synergizes with cyclophosphamide to induce potent anti-tumor vaccine effects through novel mechanisms”, Eur J Immunol. Oct. 2011;41(10):2977-86. doi: 10.1002/eji.201141639. Epub Aug. 17, 20…
[cited by applicant]
Rx Times (Apr. 11, 2016) (http://rxtimes.com/altor-bioscience-corporation-partners-with-the-national-cancer-institute-to-further-develop-altors-alt-803-and-alt-801-cancer-immunotherapeutics/).
[cited by applicant]
Notice of Reasons for Refusal received for Japanese Patent Apllication Serial No. 2018569023 dated Jan. 5, 2021, 4 pages (Including English Translation).
[cited by applicant]
Notice of Final Rejection received for Korean Patent Application Serial No. 1020197003046 dated Dec. 21, 2020, 8 pages (Including English Translation).
[cited by applicant]
Non Final Office Action received for U.S. Appl. No. 16/783,734 dated Feb. 5, 2021 45 pages.
[cited by applicant]
Mancheril et al., “Nab-Paclitaxel and Carboplatin (Nab-PC) Regimen for Advanced Non-Small-Cell Lung Cancer”, Hosp. Pharm., 2014, vol. 49, No. 9, pp. 804-808.
[cited by applicant]
Antonia et al., (International Journal of Radiation Oncology, 2014; vol. 90, Issue 5; Supplement S2; #3).
[cited by applicant]
Morishima et al., “CITN11-02 interim trial results: subcutaneous administration of recombinant human IL-15 (rhil-15) is associated with robust expansion of peripheral blood CD56+ NK cells”, Journal for Immuno Therapy of…
[cited by applicant]
Tonn et al., “Treatment of patients with advanced cancer with the natural killer cell line NK-92”, Cytotherapy, 2013, vol. 15, pp. 1563-1570.
[cited by applicant]
Request for the Submission of an Opinion received for Korean Patent Application Serial No. 20217002163 dated Mar. 5, 2021, 11 pages (Including English Translation).
[cited by applicant]
Final Office Action received for U.S. Appl. No. 16/312,246 dated Feb. 22, 2021 40 pages.
[cited by applicant]
Yu et al., “Simultaneous blockade of multiple immune system inhibitory checkpoints enhances antitumor activity mediated by interleukin-15 in a murine metastatic colon carcinoma model”, Clinical Cancer Research, 2010, vo…
[cited by applicant]
Soliman Hatem H, “nab-Paclitaxel as a potential partner with checkpoint inhibitors in solid tumors”, OncoTargets and Therapy, 2017, vol. 10, pp. 101-112.
[cited by applicant]
Acoba et al., “Phase lb/II study of ALT-803 in combination with gemcitabine and nab-paclitaxel in patients with advanced pancreatic cancer”, Journal of Clinical Oncology, 2017, vol. 35, No. 4, pp. 1-4.
[cited by applicant]
Non Final Office Action received for U.S. Appl. No. 16/312,246 dated May 14, 2021 24 pages.
[cited by applicant]
Notice of Allowance received for U.S. Appl. No. 16/783,734 dated May 19, 2021, 24 pages.
[cited by applicant]
Notice of Allowance received for U.S. Appl. No. 16/783,734 dated Jun. 18, 2021, 6 pages.
[cited by applicant]
Final Office Action received for U.S. Appl. No. 16/312,246 dated Aug. 23, 2021 18 pages.
[cited by applicant]
Notice of Allowance received for U.S. Appl. No. 16/312,246 dated Sep. 15, 2021, 12 pages.
[cited by applicant]
Office Action received for Tawainese Application Serial No. 201803598, dated Sep. 17, 2021, 12 pages (Including English Translation).
[cited by applicant]
Notice of Final Rejection received for Korean Patent Application Serial No. 1020217002163 dated Sep. 29, 2021, 9 pages (Including English Translation).
[cited by applicant]
Office Action received for Taiwanese Patent Application Serial No. 106122120 dated Sep. 17, 2021, 12 pages (Including English Translation).
[cited by applicant]
Office Action received for Taiwanese Patent Application Serial No. 106122120 dated Jan. 5, 2022, 4 pages. (Including English Translation).
[cited by applicant]
Notice of Allowance received for U.S. Appl. No. 16/312,246 dated Oct. 27, 2021, 6 pages.
[cited by applicant]
Notice of Allowance received for U.S. Appl. No. 16/312,246 dated Nov. 9, 2021, 6 pages.
[cited by applicant]
Notice of Final Rejection received for Korean Patent Application Serial No. 1020217002163 dated Dec. 7, 2021, 9 pages. (Including English Translation).
[cited by applicant]
Office Action received for Mexican Patent Application Serial No. MX/a/2018/015796 dated Oct. 28, 2021, 18 pages. (Including English Translation).
[cited by applicant]
First Office Action received for Chinese Patent Application Serial No. 201780041456.4 dated Nov. 30, 2021, 14 pages. (Including English Translation).
[cited by applicant]
Office Action received for Canadian Patent Application Serial No. 3,027,911 dated Jan. 6, 2022, 6 pages.
[cited by applicant]
Non-Final Office Action received for U.S. Appl. No. 17/391,694 dated Oct. 21, 2021, 26 pages.
[cited by applicant]
Sun et al., “Cisplatin improves antitumor activity of weekly nab-paclitaxel in patients with metastatic breast cancer”, International Journal of Nanomedicine, vol. 9. 2014, pp. 1443-1452.
[cited by applicant]
Adkins et al., “Clinical response rate at primary tumor site (PTS) following a novel induction chemotherapy (IC) regimen of weekly nanopartide albumin-bound (nab-)paditaxel and cetuximab with every-3-week cisplatin and …
[cited by applicant]
Verschaegen et al., “Avelumab (MSB001071 BC; anti-PD-L1) as a first-line treatment for patients with advanced NSCLC from the JAVELIN Solid Tumor phase 1 b trial: Safety, Clinical, activity, and PD-L1 expression”, Journa…
[cited by applicant]
Miller et al., “‘First-in-human’ phase I dose escalation trial of IL-15N72D/IL-15Ra-Fc superagonist complex (ALT-803) demonstrates immune activation with anti-tumor activity in patients with relapsed hematological malig…
[cited by applicant]
Isacoff et al., “Metronomic therapy with 5-FU, weekly nab-paditaxel, leucovorin, and oxaliplatin, plus bevacizumab for advanced pancreatic cancer: A phase II study”, Journal of Clinical Oncology, vol. 30, No. 15_suppl, …
[cited by applicant]
Hamilton et al., “Nab-Paclitaxel/Bevacizumab/Carboplatin Chemotherapy in First-Line Triple Negative Metastatic Breast Cancer”, Clinical Breast Cancer, vol. 13, 2013, pp. 416-420.
[cited by applicant]
Masci et al., “Weekly Non-pegylated Liposomal Doxorubicin Chemotherapy in Heavily Pre-treated Patients with Metastatic Breast Cancer”, Anticancer Research, vol. 33, Dec. 2013, pp. 4603-4610.
[cited by applicant]
Non-Final Office Action received for U.S. Appl. No. 17/391,694 dated Feb. 2, 2022, 20 pages.
[cited by applicant]
Notice of Allowance received for U.S. Appl. No. 17/391,694 dated May 23, 2022, 20 pages.
[cited by applicant]
Anonymous: “NCT03136406: : NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who on or After Standard-of-care Therapy”, May 25, 2017 (May 25, 2017), XP055968576, Retrieved from…
[cited by applicant]
Anonymous: “NCT03167164: NANT Merkel Cell Carcinoma (MCC) Vaccine: Combination Immunotherapy in Subjects With MCC Who on or After PD-LI Therapy”, May 23, 2017 (May 23, 2017), XP55968561, Retrieved from the Internet: URL…
[cited by applicant]
Anonymous: “NCT03167177: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progre Chemotherapy and PD-1/PD-LI Therapy”, May 24, 2017 (May 24, 2017), XP055968572, Retrieved from the Inte…
[cited by applicant]
Anonymous: “NCT03169738: : NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With N Progressed After Treatment With PD-1/PD-LI Inhibitors”, May 25, 2017 (May 25, 2017), XP055968558, …
[cited by applicant]
Anonymous: “NCT03169764: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Sub Who Have Progressed on or After Chemotherapy and PD-1/PD-LI Therapy”,May 25, 2017 (May 25, 2017), XP5…
[cited by applicant]
Extended European Search Report for EP Application No. 22182406.3 dated: Oct. 14, 2022, 11 pages.
[cited by applicant]